{"id":"NCT00927472","sponsor":"Sun Pharmaceutical Industries, Inc.","briefTitle":"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","officialTitle":"A Multi-Center Phase III Study to Evaluate Ovide Lotion 0.5% Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects With Pediculosis Capitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2010-05","completion":"2010-06","firstPosted":"2009-06-25","resultsPosted":"2014-08-04","lastUpdate":"2014-08-04"},"enrollment":254,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Pediculosis"],"interventions":[{"type":"DRUG","name":"Malathion gel 0.5%","otherNames":[]},{"type":"DRUG","name":"Permethrin 1% rinse","otherNames":["Nix Creme Rinse"]}],"arms":[{"label":"Malathion Gel","type":"EXPERIMENTAL"},{"label":"Nix Creme Rinse","type":"ACTIVE_COMPARATOR"}],"summary":"In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.","primaryOutcome":{"measure":"Proportion of Index Subjects Free of Any of Lice 14 Days After Their Last Treatment.","timeFrame":"3 weeks","effectByArm":[{"arm":"Malathion Gel","deltaMin":82.98,"sd":3.25},{"arm":"Nix Creme Rinse","deltaMin":62.5,"sd":4.95}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0386"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["17845167"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":126},"commonTop":["Application site irritation","Scab","Eye irritation","Otitis media","Pyoderma"]}}